Show simple item record

dc.contributor.authorKirchhelle, C
dc.contributor.authorAtkinson, P
dc.contributor.authorBroom, A
dc.contributor.authorChuengsatiansup, K
dc.contributor.authorFerreira, JP
dc.contributor.authorFortané, N
dc.contributor.authorFrost, I
dc.contributor.authorGradmann, C
dc.contributor.authorHinchliffe, S
dc.contributor.authorHoffman, SJ
dc.contributor.authorLezaun, J
dc.contributor.authorNayiga, S
dc.contributor.authorOutterson, K
dc.contributor.authorPodolsky, SH
dc.contributor.authorRaymond, S
dc.contributor.authorRoberts, AP
dc.contributor.authorSinger, AC
dc.contributor.authorSo, AD
dc.contributor.authorSringernyuang, L
dc.contributor.authorTayler, E
dc.contributor.authorRogers Van Katwyk, S
dc.contributor.authorChandler, CIR
dc.date.accessioned2021-01-11T15:49:27Z
dc.date.issued2020-09-23
dc.description.abstractThere is increasing concern globally about the enormity of the threats posed by antimicrobial resistance (AMR) to human, animal, plant and environmental health. A proliferation of international, national and institutional reports on the problems posed by AMR and the need for antibiotic stewardship have galvanised attention on the global stage. However, the AMR community increasingly laments a lack of action, often identified as an â € implementation gap'. At a policy level, the design of internationally salient solutions that are able to address AMR's interconnected biological and social (historical, political, economic and cultural) dimensions is not straightforward. This multidisciplinary paper responds by asking two basic questions: (A) Is a universal approach to AMR policy and antibiotic stewardship possible? (B) If yes, what hallmarks characterise â € good' antibiotic policy? Our multistage analysis revealed four central challenges facing current international antibiotic policy: metrics, prioritisation, implementation and inequality. In response to this diagnosis, we propose three hallmarks that can support robust international antibiotic policy. Emerging hallmarks for good antibiotic policies are: Structural, Equitable and Tracked. We describe these hallmarks and propose their consideration should aid the design and evaluation of international antibiotic policies with maximal benefit at both local and international scales.en_GB
dc.description.sponsorshipAntimicrobial Resistance Cross Council Initiativeen_GB
dc.description.sponsorshipEconomic and Social Research Council (ESRC)en_GB
dc.description.sponsorshipDepartment of Healthen_GB
dc.description.sponsorshipArts and Humanities Research Council (AHRC)en_GB
dc.description.sponsorshipWellcome Trusten_GB
dc.description.sponsorshipINRAEen_GB
dc.description.sponsorshipCDDEPen_GB
dc.description.sponsorshipUK Fleming Funden_GB
dc.description.sponsorshipMedical Research Council (MRC)en_GB
dc.identifier.citationVol. 5, article e003091en_GB
dc.identifier.doi10.1136/bmjgh-2020-003091
dc.identifier.grantnumberANR-18-CE03-001en_GB
dc.identifier.grantnumberMR/S004793/1en_GB
dc.identifier.urihttp://hdl.handle.net/10871/124361
dc.language.isoenen_GB
dc.publisherBMJ Publishing Groupen_GB
dc.rights© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.en_GB
dc.titleSetting the standard: Multidisciplinary hallmarks for structural, equitable and tracked antibiotic policyen_GB
dc.typeArticleen_GB
dc.date.available2021-01-11T15:49:27Z
dc.descriptionThis is the final version. Available on open access from BMJ Publishing Group via the DOI in this recorden_GB
dc.identifier.eissn2059-7908
dc.identifier.journalBMJ Global Healthen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2020-08-03
exeter.funder::Wellcome Trusten_GB
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-09-23
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-01-11T15:45:18Z
refterms.versionFCDVoR
refterms.dateFOA2021-01-11T15:49:38Z
refterms.panelCen_GB
refterms.depositExceptionpublishedGoldOA


Files in this item

This item appears in the following Collection(s)

Show simple item record

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. 
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's licence is described as © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.